according to Drug Policy 1986, and by when these would be included?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) The recommendations of the Expert Committee containing the review of drugs under Category I of Drugs (Price Control) Order, 1987 are under examination of the Ministry.

(b) The names of drugs recommended by this Ministry for inclusion in Category I on 4-6-87 is at Annexure (*See* Appendix CL, Annexure No. 38). This list was, however, shortened on the request of the Department of Chemicals and Petrochemicals which is also annexed as Annexure [*See* Appendix CL, Annexure No. 39].

(c) to (e) The list of Category I drugs as amended by the Department of Chemicals and Petro-Chemicals in January, 1989 is at Annexure [*See* Appendix CL, Annexure No. 40]. Two drugs, namely Rifampicin and Paracetamol were re-classified. Three other drugs *viz.* Sodium Sulphacetamide Drops, Timolol Maleate and Oral Rehydration Salts were not included in Category I by the Department of Chemicals & Petro-chemicals in the amended Drugs Prices Control Order, 1989, on the advice of the Kalkar Committee which was specially appointed for deciding the final inclusion of drugs for categorisation. The other drugs which were not included were vaccines required for the Universal Programme for Immunisation, drugs for the Maternal and Child Health Programme and the STD Control Programme. There are no drugs specifically for the AIDS Control Programme. The Expert Committee set up by the Ministry of Health and F. W. to review the listing of category I drugs has submitted its report. The recommendations of the Committee are under consideration of the Ministry.

Import of Triprolidine, Polymixin-B Sulphate

741. SHRI ASHOK NATH VERMA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Triprolidine, Polymixin-B Sulphate and Glipizide are being imported in the country;

(b) if so, what was the quantity imported of each during last three years, year-wise and the CIF import price of each;

(c) what is the indication for which each was cleared for human consumption in the country;

(d) the names of leading drug companies who are marketing formulations based on each drug;

(e) whether any of these drugs are used for any of the National Health Programmes;

(f) if so, the names of the drugs and the programme;

(g) whether his Ministry has declared any of these drugs non-essential; and

(h) if so, the names of those drugs?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) and (b) Information as available with this Ministry is given at Annexure [*See* Appenlix CL Annexure No. 41].

(c) and (d) As per enclosed Statement (*See* below).

(e) No, Sir.

(f) Does not arise.

(g) No, Sir.

(h) Does not arise.

Statement

Name of the Drug	Name of the drug Company	Indications
1. Triprolidine	M/s. Borroughs Wellcome, Bombay.	Nasal and respiratory, congestion, common Cold, hey fever, sinusitis elergic and Vasemeter rhinitis.
2. Polymixin-B	M/s. Berroughs Wellcome, Bombay.	Aotibacterial
	M/s. Fairdeal Corporation, Bombay.	
3. Glipizide	M/s. U.S. Vitamins, Bombay.	Diabitis.

Inclusion of Diphtheria, Tetanus and Triple Antigen under Drug Price Control Order

742. CHOWDHARY RAM SEWAK: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether his Ministry had recommended for inclusion of Diphtheria Tetanus and Triple Antigen under First Schedule of Drugs Price Control Order;

(b) whether the country has attained self-sufficiency in these products;

(c) whether Kelkar Committee has admitted that there is a surplus production thereof;

(d) whether it is also a fact that price of these vaccines have gone up by around 200 per cent.;

(e) whether it is a fact that these vaccines are used under Immunization programme; and

(f) if so, what are the reasons for non-inclusion of these vaccines under First Schedule and what steps have been taken to cover them as per Policy statement?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI (SAROJ KHAPARDE): (a) Yes, Sir.

(b) and (c) The supplementary report of the Kelkar Committee has opined that although in case of certain vaccines there are surplus production, in future, it is anticipated that biotechnological methods, which are capital intensive would replace the outdated technology.

(d) The pricing of vaccines|drugs is monitored by the Department of Chemicals and Petro-Chemicals.

(e) Yes, Sir.

(f) The reasons given in the supplementary report of the Kelkar Committee for exclusion of vaccines and Sera from the purview of price control is to motivate Indian Entreprenures to adopt newer methods of productions which are capital intensive.

Shifting the category of drugs produced from intermediate stage

743. CHOWDHARY RAM SEWAK: SHRI M. KADHARSHA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government are aware that Rifampicin is being produced from intermediate stage;

(b) whether it is a fact that this drug is needed for National Health Programme;